1752 Stock Overview
Engages in the manufacturing, processing, trading, import, and export of pharmaceuticals and medical devices in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Nang Kuang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$42.00 |
| 52 Week High | NT$58.00 |
| 52 Week Low | NT$40.10 |
| Beta | 0.27 |
| 1 Month Change | -1.52% |
| 3 Month Change | -5.62% |
| 1 Year Change | -25.13% |
| 3 Year Change | 11.11% |
| 5 Year Change | 0.72% |
| Change since IPO | 147.87% |
Recent News & Updates
Recent updates
There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings
Nov 19
Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings
May 22Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings
Apr 02Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet
Mar 20Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)
Mar 03Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?
Feb 13
Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years
Jan 26Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)
Jan 08Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend
Nov 29Shareholder Returns
| 1752 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.5% | -0.7% | 0.9% |
| 1Y | -25.1% | -3.6% | 28.9% |
Return vs Industry: 1752 underperformed the TW Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: 1752 underperformed the TW Market which returned 28.9% over the past year.
Price Volatility
| 1752 volatility | |
|---|---|
| 1752 Average Weekly Movement | 1.7% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1752 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1752's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | n/a | Yu-Bei Wang | www.nangkuang.com.tw |
Nang Kuang Pharmaceutical Co., Ltd. engages in the manufacturing, processing, trading, import, and export of pharmaceuticals and medical devices in Taiwan and internationally. The company provides parenterals, aseptic parenterals, lyophilized injections, pre-filled syringes, and pre-mixed IV infusion bags, as well as tablets, capsules, topical products, and oral suspensions. It also offers various products in the areas of cardiovascular system, gastrointestinal system, nervous system, alimentary and metabolism, blood, antineoplastic and immunomodulatory, musculo-skeletal system, respiratory system, dermatological, genito-urinary and sex hormone, systemic hormone, systemic antibacterial, and cosmetics, as well as hospital solutions.
Nang Kuang Pharmaceutical Co., Ltd. Fundamentals Summary
| 1752 fundamental statistics | |
|---|---|
| Market cap | NT$4.12b |
| Earnings (TTM) | NT$122.15m |
| Revenue (TTM) | NT$2.14b |
34.7x
P/E Ratio2.0x
P/S RatioIs 1752 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1752 income statement (TTM) | |
|---|---|
| Revenue | NT$2.14b |
| Cost of Revenue | NT$1.43b |
| Gross Profit | NT$710.25m |
| Other Expenses | NT$588.10m |
| Earnings | NT$122.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 33.24% |
| Net Profit Margin | 5.72% |
| Debt/Equity Ratio | 21.8% |
How did 1752 perform over the long term?
See historical performance and comparisonDividends
4.8%
Current Dividend Yield165%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 07:44 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nang Kuang Pharmaceutical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Yuan Lu | KGI Securities Co. Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |